VRTX FY 2025 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$129B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12.1B+9.6% YoY

Gross Profit

$10.3B85.0% margin

Operating Income

$4.8B39.4% margin

Net Income

$4.0B32.7% margin

EPS (Diluted)

$15.32

Cash Flow

Operating Cash Flow

$3.6B

Free Cash Flow

$3.2B

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$26.1B

Total Liabilities

$7.5B

Stockholders' Equity

$18.7B

Cash & Equivalents

$5.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12.1B	$11.0B	+9.6%
Gross Profit	$10.3B	$9.5B	+8.2%
Operating Income	$4.8B	-$233M	+2144.1%
Net Income	$4.0B	-$536M	+838.1%